Patterns of biologic agent utilization among patients with rheumatoid arthritis: a retrospective cohort study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2474
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Patterns of biologic agent utilization among patients with rheumatoid arthritis: a retrospective cohort study ; volume:12 ; number:1 ; day:19 ; month:9 ; year:2011 ; pages:1-11 ; date:12.2011
BMC musculoskeletal disorders ; 12, Heft 1 (19.9.2011), 1-11, 12.2011
- Urheber
-
Ogale, Sarika
- Beteiligte Personen und Organisationen
-
Hitraya, Elena
Henk, Henry J.
SpringerLink (Online service)
- DOI
-
10.1186/1471-2474-12-204
- URN
-
urn:nbn:de:1111-2016043019544
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:01 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Ogale, Sarika
- Hitraya, Elena
- Henk, Henry J.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Administration costs of intravenous biologic drugs for rheumatoid arthritis
Do biologic therapies reduce aortic inflammation in rheumatoid arthritis patients?
Disease activity and biologic use in patients with psoriatic arthritis or rheumatoid arthritis
Biologic monotherapy in the biologic naïve patient with rheumatoid arthritis (RA): results from an observational study
Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics
Economic impact of biologic utilization patterns in patients with psoriatic arthritis
Biologic and Targeted Synthetic DMARD Utilization in the United States: Adelphi Real World Disease Specific Programme for Rheumatoid Arthritis
Utilizing biologic disease-modifying anti-rheumatic treatment sequences to subphenotype rheumatoid arthritis
Safety of biologic agents after rituximab therapy in patients with rheumatoid arthritis
A Retrospective Analysis of Corticosteroid Utilization Before Initiation of Biologic DMARDs Among Patients with Rheumatoid Arthritis in the United States
Association between autophagy and inflammation in patients with rheumatoid arthritis receiving biologic therapy
Analysis of biologic therapy in rheumatoid arthritis in a southern Spanish hospital population
Administration costs of intravenous biologic drugs for rheumatoid arthritis
Do biologic therapies reduce aortic inflammation in rheumatoid arthritis patients?
Disease activity and biologic use in patients with psoriatic arthritis or rheumatoid arthritis
Biologic monotherapy in the biologic naïve patient with rheumatoid arthritis (RA): results from an observational study
Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics
Economic impact of biologic utilization patterns in patients with psoriatic arthritis
Biologic and Targeted Synthetic DMARD Utilization in the United States: Adelphi Real World Disease Specific Programme for Rheumatoid Arthritis
Utilizing biologic disease-modifying anti-rheumatic treatment sequences to subphenotype rheumatoid arthritis
Safety of biologic agents after rituximab therapy in patients with rheumatoid arthritis
A Retrospective Analysis of Corticosteroid Utilization Before Initiation of Biologic DMARDs Among Patients with Rheumatoid Arthritis in the United States
Association between autophagy and inflammation in patients with rheumatoid arthritis receiving biologic therapy
Analysis of biologic therapy in rheumatoid arthritis in a southern Spanish hospital population
Administration costs of intravenous biologic drugs for rheumatoid arthritis
Do biologic therapies reduce aortic inflammation in rheumatoid arthritis patients?
Disease activity and biologic use in patients with psoriatic arthritis or rheumatoid arthritis
Biologic monotherapy in the biologic naïve patient with rheumatoid arthritis (RA): results from an observational study
Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics
Economic impact of biologic utilization patterns in patients with psoriatic arthritis
Biologic and Targeted Synthetic DMARD Utilization in the United States: Adelphi Real World Disease Specific Programme for Rheumatoid Arthritis
Utilizing biologic disease-modifying anti-rheumatic treatment sequences to subphenotype rheumatoid arthritis
Safety of biologic agents after rituximab therapy in patients with rheumatoid arthritis
A Retrospective Analysis of Corticosteroid Utilization Before Initiation of Biologic DMARDs Among Patients with Rheumatoid Arthritis in the United States
Association between autophagy and inflammation in patients with rheumatoid arthritis receiving biologic therapy